For media interviews, contact:
Kerri Wade, MPA
kwade@smfm.org
+ 1 (202) 236-1780

FDA Issues EUA for the Treatment of Mild-to-Moderate COVID-19

Maternal-Fetal Medicine Subspecialists Support Use in Pregnant Patients

December 22, 2021 – Today the U.S. Food and Drug Administration issued an Emergency Use Authorization (EUA) for Paxlovid for the treatment of mild-to-moderate COVID-19 in adults and some pediatric patients. In response, the Society for Maternal-Fetal Medicine (SMFM) issued the following statement.

"SMFM supports the use of Paxlovid (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) for treatment of pregnant patients with COVID-19 who meet clinical qualifications. Any therapy that would otherwise be given should not be withheld specifically due to pregnancy or lactation."

###

About SMFM

The Society for Maternal-Fetal Medicine (SMFM), founded in 1977, is the medical professional society for obstetricians who have additional training in high-risk, complicated pregnancies. SMFM represents more than 5,000 members who care for high-risk pregnant people and provides education, promotes research, and engages in advocacy to reduce disparities and optimize the health of high-risk pregnant people and their families. SMFM and its members are dedicated to optimizing maternal and fetal outcomes and assuring medically appropriate treatment options are available to all patients.